Studies Support Cordis Selution SLR Drug-Eluting Balloon
Cordis announced new findings from two studies supporting the use of its Selution SLR drug-eluting balloon system.
The SELUTION DeNovo and SELUTION 4ISR trials, presented at the 2025 Transcatheter Cardiovascular Therapeutics conference, demonstrated positive outcomes that met primary endpoints.
- Selution SLR performed well in treating de novo and in-stent restenosis coronary lesions.
- The system offers a compelling alternative to drug-eluting stents, minimizing the need for common stent offerings.
Selution SLR provides a controlled sustained drug release, similar to a drug-eluting stent, with unique micro-reservoirs made of biodegradable polymer intermixed with sirolimus.
Author's summary: Cordis Selution SLR drug-eluting balloon shows positive results.
More News
- Moody’s maintains BPC rating despite gov't downgrade
- The Turkish glees, language barrier
- Two US Navy Aircraft and a Helicopter Crash in South China Sea, All Crew Rescued
- Older Patients and Women Bear the Brunt of CTD-ILD Burden
- Angola seeks to purchase Anglo American’s 85% stake in De Beers
- The opposite of “turbo cancer”: COVID-19 vaccines sensitize cancer to immunotherapy
- Review: Bruce Springsteen biopic delivers authenticity and artistry - Washington Square News
- The main PlayStation Plus Essential monthly game for November has seemingly been leaked | VGC
- Health Canada Grants Authorization for LEQEMBI® (lecanemab) for the Treatment of Early Alzheimer's Disease
- KLEIN: Ford and Kinew - Political theatre isn’t leadership, it’s embarrassment